FDA-2026-P-3104

Requests that the FDA makes the determination that CABAZITAXEL injection for intravenous use 60 mg/6 mL (10 mg/mL) [NDA 207970] held by Actavis, LLC, an indirect, wholly-owned subsidiary of Teva Pharmaceuticals USA, Inc. was not discontinued for reasons of safety or effectiveness.